5AM Ventures led a $54.5m seed funding round in Renasant.

5AM Ventures, a venture capital firm, led a $54.5m seed funding round in Renasant, a biopharmaceutical company, with participation from Atlas Venture, OrbiMed, and Qiming Ventures. “ADPKD is a devastating genetic disorder that affects more than 12 million people globally and still lacks truly disease-modifying therapies. Our platform of differentiated correctors and first-in-class potentiator therapies are designed to directly address the underlying cause of ADPKD across its broad mutation spectrum, offering the potential to benefit the vast majority of patients,” Emily Conley, Renasant CEO.